Healthcare ❯ Drug Development

Regulatory Approval

FDA Processes Clinical Trials FDA Safety Trials

Vertex’s IgA Nephropathy Drug Hits Phase 3 Goals, FDA Filing Slated for March

The company plans to use a priority review voucher to pursue a roughly six‑month decision from the FDA.

Bristol Myers Gains Analyst Support as 2026 Catalysts Offset Patent-Cliff Worries

Lilly’s Oral GLP-1 Pill Meets Phase 3 Goals, Shares Rebound